NICE recommends Celgene VIZADA for use in the NHS in England, Wales
NICE’s evaluation took into account peer-reviewed clinical studies that demonstrated VIDAZA as an innovative epigenetic, life-extending, cost-effective therapy for the National Health Service (NHS). Celgene Corporation CEO Robert
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.